| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | John Riley | Q59677041 |
| P2093 | author name string | Douglas H Smith | |
| Khalil Bdeir | |||
| Xiao-Han Chen | |||
| Douglas B Cines | |||
| Kumkum Ganguly | |||
| Vladimir R Muzykantov | |||
| William M Armstead | |||
| Sherman C Stein | |||
| Sergei Zaitsev | |||
| Abd A R Higazi | |||
| J W Kiessling | |||
| P2860 | cites work | Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor | Q24564351 |
| Astrocyte-endothelial interactions at the blood-brain barrier | Q28131675 | ||
| Cerebral sinovenous thrombosis in children | Q28211927 | ||
| Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator | Q28373854 | ||
| Key role of tissue plasminogen activator in neurovascular coupling | Q28512912 | ||
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| Neurovascular regulation in the normal brain and in Alzheimer's disease | Q29619659 | ||
| Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis | Q30444430 | ||
| Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke | Q30586020 | ||
| Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice | Q30657503 | ||
| Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats | Q30867728 | ||
| Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample | Q31109188 | ||
| The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. | Q31793818 | ||
| Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo | Q33227064 | ||
| Advances in ischemic stroke treatment: neuroprotective and combination therapies | Q33278117 | ||
| Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke | Q33610598 | ||
| Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy | Q33691638 | ||
| Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors | Q33722964 | ||
| Stroke in newborn infants | Q34300601 | ||
| Protein kinase C and cerebral vasospasm | Q34327417 | ||
| Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents | Q34432109 | ||
| Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment | Q34566668 | ||
| Mechanisms, challenges and opportunities in stroke | Q35120144 | ||
| Cerebral microvessel responses to focal ischemia | Q35193869 | ||
| Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation | Q35214038 | ||
| The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors | Q35318104 | ||
| Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. | Q35751067 | ||
| uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. | Q36512703 | ||
| Neuroserpin, an axonally secreted serine protease inhibitor | Q36803721 | ||
| uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK | Q36948533 | ||
| Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. | Q36991072 | ||
| The cost of pediatric stroke acute care in the United States | Q37037725 | ||
| Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia | Q37138982 | ||
| Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke? | Q37207243 | ||
| Treating acute ischemic stroke | Q37252854 | ||
| Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator | Q37263891 | ||
| Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia | Q37271168 | ||
| Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation | Q37285884 | ||
| Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. | Q37301824 | ||
| Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. | Q37311853 | ||
| Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature. | Q37322682 | ||
| Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential | Q37367536 | ||
| Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury | Q37397703 | ||
| Desmoteplase | Q37489895 | ||
| The later growth of the brain and its vulnerability | Q39934695 | ||
| Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke | Q40119775 | ||
| New pediatric model of ischemic stroke in infant piglets by photothrombosis: acute changes in cerebral blood flow, microvasculature, and early histopathology | Q40219039 | ||
| Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling | Q40511087 | ||
| Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice | Q40870073 | ||
| Experimental acute subdural hematoma in infant piglets | Q40927194 | ||
| Regulation of the cerebral circulation: role of endothelium and potassium channels | Q41697441 | ||
| Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background | Q41701943 | ||
| Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke | Q41817443 | ||
| Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion | Q42505289 | ||
| Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats | Q43730509 | ||
| Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction | Q44097437 | ||
| Age dependent NMDA contribution to impaired hypotensive cerebral hemodynamics following brain injury | Q44203389 | ||
| In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone | Q44598246 | ||
| Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke | Q46352189 | ||
| Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. | Q46624722 | ||
| Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury | Q46649425 | ||
| Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice | Q46893038 | ||
| Plasminogen potentiates thrombin cytotoxicity and contributes to pathology of intracerebral hemorrhage in rats | Q46947348 | ||
| LRP and alphavbeta3 mediate tPA activation of smooth muscle cells | Q46952849 | ||
| Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. | Q47733979 | ||
| The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. | Q48182042 | ||
| Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. | Q48228189 | ||
| Neutralizing the neurotoxic effects of exogenous and endogenous tPA. | Q48435483 | ||
| Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice | Q48589075 | ||
| Blood clearance and activity of erythrocyte-coupled fibrinolytics. | Q50782336 | ||
| NOC/oFQ contributes to age-dependent impairment of NMDA-induced cerebrovasodilation after brain injury. | Q51374765 | ||
| Role of endothelin-1 in age-dependent cerebrovascular hypotensive responses after brain injury. | Q51433209 | ||
| Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. | Q52051559 | ||
| Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) | Q55063586 | ||
| Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells | Q70507044 | ||
| Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors | Q73048905 | ||
| Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats | Q73274588 | ||
| Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes | Q73621576 | ||
| tPA and proteolysis in the neurovascular unit | Q75392815 | ||
| Taming the clot-buster tPA | Q80230629 | ||
| Intra-arterial thrombolysis in a 2-year-old with cardioembolic stroke | Q80590928 | ||
| NXY-059 for the treatment of acute ischemic stroke | Q80768385 | ||
| Neonatal brain injury | Q80961596 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 303-312 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders | |
| P478 | volume | 113 |
| Q37132620 | Advanced drug delivery systems for antithrombotic agents. |
| Q21284798 | Biomedical and clinical promises of human pluripotent stem cells for neurological disorders |
| Q34990098 | Comparison of surgical methods of transient middle cerebral artery occlusion between rats and mice |
| Q26801300 | Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier |
| Q41959866 | Effects of skilled reach training with affected forelimb and treadmill exercise on the expression of neurotrophic factor following ischemia-induced brain injury in rats. |
| Q42747557 | Gastrodia and Uncaria (tianma gouteng) water extract exerts antioxidative and antiapoptotic effects against cerebral ischemia in vitro and in vivo |
| Q36464003 | MiR-126 Contributes to Human Umbilical Cord Blood Cell-Induced Neurorestorative Effects After Stroke in Type-2 Diabetic Mice |
| Q37102334 | MicroRNAs in cerebral ischemia-induced neurogenesis |
| Q34096191 | Middle cerebral artery occlusion methods in rat versus mouse models of transient focal cerebral ischemic stroke |
| Q34558344 | Middle cerebral artery occlusion model in rodents: methods and potential pitfalls |
| Q89537192 | Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies |
| Q38091111 | Perlecan domain V therapy for stroke: a beacon of hope? |
| Q36748046 | RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis |
| Q38760096 | Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems |
| Q54983745 | Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK. |
| Q35772501 | Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke |
| Q38099859 | Targeting nitric oxide in the subacute restorative treatment of ischemic stroke |
| Q48132273 | tPA variant tPA-A296-299 Prevents impairment of cerebral autoregulation and necrosis of hippocampal neurons after stroke by inhibiting upregulation of ET-1. |
Search more.